This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-02. Anything still debated is marked as such rather than presented as settled.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
Handling recommendations for SR9009 in a laboratory setting include storing the solid at low temperature, protected from light and moisture. The compound is often dissolved in dimethyl sulfoxide or ethanol for experiments. Solutions should be prepared with appropriate personal protective equipment and disposed of according to local rules. Stability data for long-term storage are limited, so stock solutions are typically kept cold and used within defined periods. Records of preparation date and concentration support reproducibility.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Laboratory samples of SR9009 are typically supplied as a white to off-white powder. The compound dissolves readily in organic solvents such as dimethyl sulfoxide and ethanol, while its solubility in water is low. Because of this solubility profile, researchers often prepare concentrated stock solutions in an organic solvent before diluting them into aqueous assay buffers. Light exposure, moisture, and repeated freeze-thaw cycles can degrade many small molecules, so handling procedures usually aim to minimize these factors. Purity is commonly checked before use.
Storage conditions for research-grade SR9009 generally involve a freezer at approximately minus twenty degrees Celsius, sometimes lower for long-term preservation. Containers should remain tightly closed and protected from light. Desiccants may be used to limit moisture uptake. Solutions are often stored in aliquots to avoid repeated warming and cooling. Stability data for the compound under various conditions are limited, so laboratories typically follow supplier recommendations and verify performance through periodic analytical checks rather than assuming indefinite stability.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
== Description == Eupolyphaga sinensis is often described as a wingless cockroach, this however is not entirely true. E. sinensis is a sexually dimorphic species, with the females being wingless, while the males are winged. Females are generally larger in size and darker in color than males. Within their range E. sinensis display significant size differences based on temperature and latitude. Body size of both males and females increase at high and low latitudes, with those found at an intermediate range being smaller. This body size difference is a result of genetic differentiation between populations, being adapted to their native climate.
=== Major warlord === Liu continued amassing power throughout 1927. In June, he attacked the forces of Liu Chengxun, who had been appointed by the Nationalists as the commander of the Sichuan-Xikang Defence Force. According to Liu's state-sanctioned biography, Liu Chengxun was highly corrupt, collecting taxes in advance and levying a dizzying array of new payments, including a "birthday tax" and a "revolution tax". Liu Wenhui issued a proclamation denouncing Liu Chengxun's oppression and corruption and appealing to other warlords to launch a joint expedition against him; his clique proceeded to collapse without a fight, with many subordinates defecting to Liu Wenhui. By December 1927, he had taken control of the Sichuan-Xikang Defence Force, gaining power over the Chinese-controlled regions of Kham. Liu Chengxun returned to Dayi County, living in obscurity under a state of virtual house arrest by Liu Wenhui's forces. Also in late 1927, Liu Wenhui attacked Lai Xinhui to connect his territories with Liu Xiang's, capturing Yongchuan, Jiangjin, and Hejiang and forcing Lai to flee to Guizhou. Liu enlisted the communist activist Li Jingxuan to set up a propaganda committee, which played a role in the defeat of Liu Chengxun. After entering Liu Chengxun's territories, Liu Wenhui declared an end to oppressive taxes, and local gentry printed propaganda declaring support for his rule as a "true revolutionary".
The trial, carried out between 1946 and 1947, aimed to test the efficacy of the chemical streptomycin for curing pulmonary tuberculosis. The trial was both double-blind and placebo-controlled. The methodology of clinical trials was further developed by Sir Austin Bradford Hill, who had been involved in the streptomycin trials. From the 1920s, Hill applied statistics to medicine, attending the lectures of renowned mathematician Karl Pearson, among others. He became famous for a landmark study carried out in collaboration with Richard Doll on the correlation between smoking and lung cancer. They carried out a case-control study in 1950, which compared lung cancer patients with matched control and also began a sustained long-term prospective study into the broader issue of smoking and health, which involved studying the smoking habits and health of more than 30,000 doctors over a period of several years. His certificate for election to the Royal Society called him "the leader in the development in medicine of the precise experimental methods now used nationally and internationally in the evaluation of new therapeutic and prophylactic agents". The ethics of selecting clinical trial subjects have been controversial for much of their modern history, especially in the United States. From the 1950s up until the early 1970s, the vast majority of pharmaceutical testing in America was performed on prison populations; only after widespread abuse during testing was reported at the Holmesburg Prison did research diminish in these areas.
=== DMPK, ADME, and bioanalysis === BioDuro conducts in vitro ADME assays, in vivo PK/TK studies, metabolic stability studies, and bioanalytical method development using LC–MS/MS platforms. These services are used to characterize compound absorption, distribution, metabolism, and excretion profiles during preclinical development.
Sources: en.wikipedia.org
The physiological role for responses to these, and several other glycoprotein hormones, is not fully understood, although it is likely that ACTH is bifunctional, like PTH, supporting bone formation with periodic spikes of ACTH, but causing bone destruction in large concentrations. In mice, mutations that reduce the efficiency of ACTH-induced glucocorticoid production in the adrenals cause the skeleton to become dense (osteosclerotic bone).
== External links == Cartilage.org, International Cartilage Regeneration & Joint Preservation Society KUMC.edu Archived 2011-04-08 at the Wayback Machine, Cartilage tutorial, University of Kansas Medical Center Bartleby.com, text from Gray's anatomy MadSci.org, I've heard 'Ears and nose do not ever stop growing.' Is this false? CartilageHealth.com, Information on Articular Cartilage Injury Prevention, Repair and Rehabilitation About.com Archived 2011-07-07 at the Wayback Machine, Osteoarthritis Cartilage types[link removed] Different cartilages on TheFreeDictionary Cartilage photomicrographs
=== Voice acting === As an actor, French appeared on the 1996 NBC miniseries Pandora's Clock as a non-commissioned officer. He was best known for voice acting work in video games by Valve Corporation, most notably Father Grigori in Half-Life 2, Bill in Left 4 Dead and Left 4 Dead 2 and the Elder Titan in Dota 2. He additionally voiced the Scientist in Gunman Chronicles and the Fisherman in the tech demo Half-Life 2: Lost Coast.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.